The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus <scp>CHOP</scp> in patients with newly diagnosed peripheral T‐cell lymphoma with analysis of biomarkers

Ling Li(First Affiliated Hospital of Zhengzhou University), Mingzhi Zhang(Chinese Academy of Sciences), Xin Li(China Medical University), Xinhua Wang(Zhengzhou University), Lei Zhang(First Affiliated Hospital of Zhengzhou University), Jingjing Wu(Beijing Tian Tan Hospital), Zhaoming Li(First Affiliated Hospital of Zhengzhou University), Zhenchang Sun(First Affiliated Hospital of Zhengzhou University), Wenjing Duan(Hebei Agricultural University), Xiaorui Fu(First Affiliated Hospital of Zhengzhou University), Yu Chang(Jilin University), Xudong Zhang(First Affiliated Hospital of Zhengzhou University), Feifei Nan(First Affiliated Hospital of Zhengzhou University), Jiaqin Yan(First Affiliated Hospital of Zhengzhou University), Ken H. Young(Duke Medical Center)
British Journal of Haematology
June 9, 2017
10.1111/bjh.14763
Cited by 35

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
|Blood|2017|429
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma
|Journal of Clinical Oncology|2015|418
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396